Shares of Merus NV MRUS rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administration has granted one of its cancer treatments a breakthrough therapy designation, intended for expedite the development and review of a drug to treat serious illness. The drug, zenocutuzumab, is geared to the treatment of patients with a type of advanced, metastatic pancreatic cancer.
... Shares of Merus NV MRUS rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administration has granted one of its cancer treatments a breakthrough therapy designation, intended for expedite the development and review of a drug to treat serious illness. The drug, zenocutuzumab, is geared to the treatment of patients with a type of advanced, metastatic pancreatic cancer.